U.S. FOOD & DRUG ADMINISTRATION

Suitability Petition
Completeness Assessment Correspondence

Pharmobedient Consulting, LLC
642 N.E. 3rd Avenue
Fort Lauderdale, FL 33304
Attn: Anthony LaViola

Sent via email to: anthony@pharmobedient.com

Docket No. FDA-2024-P-1788

Dear Anthony LaViola:

This is in reference to your petition received on April 10, 2024, by the U.S. Food and Drug Administration (FDA or Agency), requesting permission, in accordance with 21 C.F.R. §314.93(b), to submit an Abbreviated New Drug Application (ANDA) for the following drug product: Carbinoxamine Maleate Tablets, 2 mg. The petition was examined for initial completeness (i.e. Completeness Assessment) under CFR 10.30 and the Agency has made a threshold determination that the petition is complete.

This petition is subject to the provisions of the Generic Drugs User Fee Amendments of 2022 (GDUFA III) whereby any suitability petitions submitted in FY 2024-2027 will receive a goal date of 6 months after the completeness assessment. The GDUFA goal date for review of this petition is October 18, 2024.

If you have any questions, contact ANDAFiling@fda.hhs.gov.

A copy of this letter will be placed on public display in the Dockets Management Branch, Room 1061, Mail Stop HFA-305, 5630 Fishers Lane, Rockville, MD 20852.

Sincerely,

{See appended electronic signature page}

Elizabeth Kim, MSN, APRN, FNP-BC
Regulatory Officer
Division of Filing Review
Office of Regulatory Operations
Office of Generic Drugs
Center for Drug Evaluation and Research

U.S. Food & Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
www.fda.gov

Elizabeth Kim

Digitally signed by Elizabeth Kim
Date: 4/18/2024 11:39:54AM
GUID: 5589699300c03b18e9f30807f0193d16